Q1 2023 Net Sales of $73.5 Million; ICL Sales
of $70.6 Million Up 20% Y/Y
Fiscal 2023 Net Sales Outlook Raised to $348
Million; ICL Sales to $345 Million Up 28% Y/Y
STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer and marketer of implantable lenses for the eye, today
reported financial results for the first quarter ended March 31,
2023.
First Quarter 2023
Overview
- Net Sales of $73.5 Million Up 16% and Constant Currency Net
Sales of $75.5 Million Up 20% Y/Y
- ICL Sales of $70.6 Million Up 20% and Constant Currency ICL
Sales of $72.4 Million Up 23% Y/Y
- ICL Units Up 20% Y/Y
- Gross Margin at 78.3% vs. 77.9% in the Prior Year Quarter
- Net Income of $0.05 per Share vs. $0.19 per Share in the Prior
Year Quarter
- Cash, Cash Equivalents and Investments Available for Sale Ended
the Quarter at $217.3 Million
“STAAR’s performance in the first quarter demonstrates the
global strength of our business with ICL units and sales both up
20% over the prior year as surgeons and patients seeking visual
freedom from glasses and contact lenses increasingly make our EVO
ICL lenses their first choice,” said Tom Frinzi, President and CEO
of STAAR Surgical. “Strength in our business during the quarter was
broad-based across APAC, EMEA and the U.S. In China, ICL procedure
volumes increased strongly in the first quarter of 2023 with
end-market procedures reaching a record level. We are maintaining a
keen focus on execution against our targeted priorities and
anticipate accelerating sales momentum as we move through the year.
We are therefore raising our outlook for fiscal 2023 net sales from
$340 million to approximately $348 million, which includes
approximately $3 million of Other Product sales in the first
quarter. Our updated outlook represents 28% global ICL sales growth
year over year.”
Financial Overview – Q1
2023
Net sales were $73.5 million for the first quarter of 2023, up
16% compared to $63.2 million reported in the prior year quarter.
Changes in currency, primarily the Japanese Yen as well as the
Euro, negatively impacted reported net sales by $2.0 million for
the first quarter of 2023. The sales increase in the first quarter
was driven by ICL sales and unit growth which were each 20%, as
compared to the prior year period. Other Product sales decreased
36% compared to the prior year quarter. ICL sales were 96% of total
net sales for the first quarter of 2023.
Gross profit margin for the first quarter of 2023 was 78.3%
compared to the prior year quarter of 77.9%. Factors impacting the
favorability in gross margin in the first quarter of 2023, as
compared to the prior year quarter, include product and geographic
mix, partially offset by increased period costs associated with
manufacturing projects.
Operating expenses for the first quarter of 2023 were $54.8
million compared to the prior year quarter of $37.2 million.
General and administrative expenses were $18.1 million compared to
the prior year quarter of $11.9 million. The increase in general
and administrative expenses was due to increased compensation
related expenses, outside services and facilities costs. Selling
and marketing expenses were $26.4 million compared to the prior
year quarter of $17.3 million. The increase in selling and
marketing expenses is due to increased advertising and promotional
activities, compensation related expenses and trade shows and sales
meetings. Research and development expenses were $10.3 million
compared to the prior year quarter of $7.9 million. The increase in
research and development expenses is due to increased compensation
related expenses and clinical trial expenses related to U.S.
post-approval studies.
Net income for the first quarter of 2023 was $2.7 million or
$0.05 per diluted share compared with net income of $9.6 million or
$0.19 per diluted share for the prior year quarter. The year over
year decrease in net income is attributable to higher operating
expenses partially offset by higher gross profit and interest
income. Adjusted Net Income for the first quarter of 2023 was $8.7
million or $0.18 per diluted share compared to $14.4 million or
$0.29 per diluted share for the prior year quarter. The
reconciliation between GAAP and non-GAAP financial information is
provided in the financial tables included with this release.
Cash, cash equivalents, short-term and long-term investments
available for sale at March 31, 2023, totaled $217.3 million,
compared to $225.5 million at end of the fourth quarter of
2022.
Conference Call
The Company will host a conference call and webcast today,
Wednesday, May 3 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to
discuss its financial results and operational progress. To access
the conference call (Access Code 835957), please dial 833-470-1428
for domestic participants and 404-975-4839 for international
participants. The live webcast can be accessed from the investor
relations section of the STAAR website at www.staar.com.
A taped replay of the conference call (Replay Code 208036) will
be available beginning approximately one hour after the call’s
conclusion for seven days. This replay can be accessed by dialing
866-813-9403 for domestic callers and 929-458-6194 for
international callers. An archived webcast will also be available
at www.staar.com.
Use of Non-GAAP Financial
Measures
This press release includes supplemental non-GAAP financial
information, which STAAR believes investors will find helpful in
understanding its operating performance. “Adjusted Net Income”
excludes the following items that are included in “Net Income” as
calculated in accordance with U.S. generally accepted accounting
principles (“GAAP”): gain or loss on foreign currency transactions,
stock-based compensation expenses, and valuation allowance
adjustments. Management believes that “Adjusted Net Income” is
useful to investors in gauging the outcome of the key drivers of
the business performance: the ability to increase sales revenue and
our ability to increase profit margin by improving the mix of high
value products while reducing the costs over which management has
control.
Management has excluded gains and losses on foreign currency
transactions because of the significant fluctuations that can
result from period to period as a result of market driven factors.
Stock-based compensation expenses consist of expenses for stock
options and restricted stock under the Financial Accounting
Standards Board’s Accounting Standards Codification (ASC) 718.
Valuation allowance adjustments can occur from time to time based
on forecasted changes in operating results until all net operating
loss carryforwards are fully utilized. In calculating Adjusted Net
Income, STAAR excludes stock-based compensation expenses and
valuation allowance adjustments because they are non-cash expenses
and because of the considerable judgment involved in calculating
their values. In addition, these expenses tend to be driven by
fluctuations in the price of our stock and not by the same factors
that generally affect our other business expenses.
The Company also uses Constant Currency as a Non-GAAP financial
measure to exclude the effects of currency fluctuations on net
sales. The Company conducts a significant part of its activities
outside the U.S. It receives sales revenue and pays expenses
principally in U.S. dollars, Swiss francs, Japanese yen and euros.
The exchange rates between dollars and non-U.S. currencies can
fluctuate greatly and can have a significant effect on the
Company’s results when reported in U.S. dollars. In order to
compare the Company's performance from period to period without the
effect of currency, the Company will apply the same average
exchange rate applicable in the prior period, or the "constant
currency" rate to sales or expenses in the current period as well.
Because changes in currency are outside of the control of the
Company and its managers, management finds this non-GAAP measure
useful in determining the long-term progress of its initiatives and
determining whether its managers are achieving their performance
goals. The Company believes that the non-GAAP constant-currency
sales results measures provided in this press release are similarly
useful to investors to give insight on long term trends in the
Company's performance without the external effect of changes in
relative currency values. The table provided in this press release
shows sales results calculated in accordance with GAAP, the effect
of currency, and the resulting non-GAAP measure expressed in
constant currency.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 40 years, designs, develops, manufactures and markets
implantable lenses for the eye. These lenses are intended to
provide visual freedom for patients, lessening or eliminating the
reliance on glasses or contact lenses. All of these lenses are
foldable, which permits the surgeon to insert them through a small
incision. STAAR’s lens used in refractive surgery is called an
Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™
product line. More than 2,000,000 ICLs have been sold to date and
STAAR markets these lenses in over 75 countries. To learn more
about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA,
the company operates manufacturing and packaging facilities in
Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more
information, please visit the Company’s website at
www.staar.com.
Safe Harbor
All statements that are not statements of historical fact are
forward-looking statements, including statements about any of the
following: any financial projections (including sales), plans,
strategies, and objectives of management for 2023 or prospects for
achieving such plans, expectations for sales, revenue, margin,
expenses or earnings, and any statements of assumptions underlying
any of the foregoing, including those relating to financial
performance in the second quarter and fiscal year 2023. Important
factors that could cause actual results to differ materially from
those indicated by such forward-looking statements include risks
and uncertainties related to the COVID-19 pandemic and related
public health measures, as well as the factors set forth in the
Company’s Annual Report on Form 10-K for the year ended December
30, 2022 under the caption “Risk Factors,” which is on file with
the Securities and Exchange Commission and available in the
“Investor Information” section of the company’s website under the
heading “SEC Filings.” We disclaim any intention or obligation to
update or revise any financial projections or forward-looking
statement due to new information or events. These statements are
based on expectations and assumptions as of the date of this press
release and are subject to numerous risks and uncertainties, which
could cause actual results to differ materially from those
described in the forward-looking statements. The risks and
uncertainties include the following: global economic conditions;
the impact of the COVID-19 pandemic on markets; the discretion of
regulatory agencies to approve or reject existing, new or improved
products, or to require additional actions before approval, or to
take enforcement action; international trade disputes; and the
willingness of surgeons and patients to adopt a new or improved
product and procedure.
Consolidated Balance Sheets (in 000's)
Unaudited ASSETS March 31,2023
December 30,2022 Current assets: Cash and cash equivalents
$
89,968
$
86,480
Investments available for sale
113,879
125,159
Accounts receivable trade, net
63,494
62,447
Inventories, net
27,808
24,161
Prepayments, deposits, and other current assets
17,722
13,476
Total current assets
312,871
311,723
Investments available for sale
13,445
13,902
Property, plant, and equipment, net
53,453
50,921
Finance lease right-of-use assets, net
303
342
Operating lease right-of-use assets, net
31,182
30,270
Intangible assets, net
165
173
Goodwill
1,786
1,786
Deferred income taxes
4,744
4,824
Other assets
956
957
Total assets
$
418,905
$
414,898
LIABILITIES AND STOCKHOLDERS' EQUITY Current
liabilities: Accounts payable
$
9,102
$
11,576
Obligations under finance leases
171
169
Obligations under operating leases
3,538
3,524
Allowance for sales returns
5,303
5,706
Other current liabilities
28,949
30,741
Total current liabilities
47,063
51,716
Obligations under finance leases
167
210
Obligations under operating leases
28,030
27,136
Deferred income taxes
1,369
1,489
Asset retirement obligations
218
220
Pension liability
3,134
1,935
Total liabilities
79,981
82,706
Stockholders' equity: Common stock
483
482
Additional paid-in capital
409,303
404,189
Accumulated other comprehensive income (loss)
(937
)
156
Accumulated deficit
(69,925
)
(72,635
)
Total stockholders' equity
338,924
332,192
Total liabilities and stockholders' equity
$
418,905
$
414,898
Consolidated Statements of Income (In 000's except for
per share data) Unaudited Three Months
Ended % of March 31, 2023 % of April 1,
2022 Fav (Unfav) Sales Sales Amount
% Net sales
100.0%
$
73,528
100.0%
$
63,200
$
10,328
16.3%
Cost of sales
21.7%
15,966
22.1%
13,936
(2,030
)
-14.6%
Gross profit
78.3%
57,562
77.9%
49,264
8,298
16.8%
Selling, general and administrative expenses: General and
administrative
24.7%
18,098
18.9%
11,940
(6,158
)
-51.6%
Selling and marketing
35.8%
26,354
27.3%
17,270
(9,084
)
-52.6%
Research and development
14.0%
10,310
12.6%
7,941
(2,369
)
-29.8%
Total selling, general, and administrative expenses
74.5%
54,762
58.8%
37,151
(17,611
)
-47.4%
Operating income
3.8%
2,800
19.1%
12,113
(9,313
)
-76.9%
Other income (expense), net: Interest income (expense), net
2.5%
1,822
0.0%
(6
)
1,828
30466.7%
Gain (loss) on foreign currency transactions
0.0%
34
-1.4%
(915
)
949
103.7%
Royalty income
0.0%
0
0.4%
273
(273
)
-100.0%
Other income, net
0.1%
63
0.1%
62
1
1.6%
Total other income (expense), net
2.6%
1,919
-0.9%
(586
)
2,505
427.5%
Income before provision for income taxes
6.4%
4,719
18.2%
11,527
(6,808
)
-59.1%
Provision for income taxes
2.7%
2,009
3.0%
1,925
(84
)
-4.4%
Net income
3.7%
$
2,710
15.2%
$
9,602
$
(6,892
)
-71.8%
Net income per share - basic
$
0.06
$
0.20
Net income per share - diluted
$
0.05
$
0.19
Weighted average shares outstanding - basic
48,247
47,755
Weighted average shares outstanding - diluted
49,500
49,288
Consolidated Statements of Cash Flows (in 000's)
Unaudited Three Months Ended March 31, 2023
April 1, 2022 Cash flows from operating activities: Net
income
$
2,710
$
9,602
Adjustments to reconcile net income to net cash used in operating
activities: Depreciation of property and equipment
1,113
994
Amortization of long-lived intangibles
7
8
Accretion/Amortization of investments available for sale
(983
)
-
Deferred income taxes
57
-
Change in net pension liability
(13
)
41
Stock-based compensation expense
6,065
3,894
Provision for sales returns and bad debts
(377
)
(194
)
Inventory provision
614
434
Changes in working capital: Accounts receivable
(1,110
)
(3,927
)
Inventories
(3,920
)
(1,483
)
Prepayments, deposits and other current assets
(4,249
)
(4,505
)
Accounts payable
(3,168
)
2,668
Other current liabilities
(1,840
)
(12,142
)
Net cash used in operating activities
(5,094
)
(4,610
)
Cash flows from investing activities: Acquisition of
property and equipment
(2,901
)
(2,539
)
Purchase of investments available for sale
(27,445
)
-
Proceeds from sale or maturity of investments available for sale
40,279
-
Net cash provided by (used in) investing activities
9,933
(2,539
)
Cash flows from financing activities: Repayment of finance
lease obligations
(42
)
(18
)
Repurchase of employee common stock for taxes withheld
(1,849
)
-
Proceeds from vested restricted stock and exercise of stock options
530
912
Net cash provided by (used in) financing activities
(1,361
)
894
Effect of exchange rate changes on cash and cash equivalents
10
(384
)
Increase (decrease) in cash and cash equivalents
3,488
(6,639
)
Cash and cash equivalents, at beginning of the period
86,480
199,706
Cash and cash equivalents, at end of the period
$
89,968
$
193,067
Reconciliation of Non-GAAP Financial Measure Adjusted Net
Income and Net Income Per Share (in 000's)
Unaudited Three Months Ended March 31, 2023
April 1, 2022 Net income (as reported)
$
2,710
$
9,602
Less: Foreign currency impact
(34
)
915
Stock-based compensation expense
6,065
3,894
Net income (adjusted)
$
8,741
$
14,411
Net income per share, basic (as reported)
$
0.06
$
0.20
Foreign currency impact
-
0.02
Stock-based compensation expense
0.13
0.08
Net income per share, basic (adjusted)
$
0.18
$
0.30
Net income per share, diluted (as reported)
$
0.05
$
0.19
Foreign currency impact
-
0.02
Stock-based compensation expense
0.12
0.08
Net income per share, diluted (adjusted)
$
0.18
$
0.29
Weighted average shares outstanding - Basic
48,247
47,755
Weighted average shares outstanding - Diluted
49,500
49,288
Note: Net income per share (adjusted), basic and diluted,
may not add due to rounding
STAAR Surgical Company
Reconciliation of Non-GAAP Financial Measure Constant
Currency Sales (in 000's) Unaudited
Three Months Ended
March 31, 2023
Effect of
Constant
April 1, 2022
As Reported
Constant Currency
Sales
Currency
Currency
$ Change
% Change
$ Change
% Change
ICL
$
70,625
$
1,726
$
72,351
$
58,675
$
11,950
20.4%
$
13,676
23.3%
Cataract IOL
1,476
157
1,633
2,902
(1,426
)
-49.1%
(1,269
)
-43.7%
Other
1,427
127
1,554
1,623
(196
)
-12.1%
(69
)
-4.3%
Other Products
2,903
284
3,187
4,525
(1,622
)
-35.8%
(1,338
)
-29.6%
Total Sales
$
73,528
$
2,010
$
75,538
$
63,200
$
10,328
16.3%
$
12,338
19.5%
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230503005843/en/
Investors and Media Brian Moore Vice President, Investor,
Media Relations and Corporate Development (626) 303-7902, Ext. 3023
bmoore@staar.com
STAAR Surgical (NASDAQ:STAA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
STAAR Surgical (NASDAQ:STAA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024